Russian steel maker NLMK Group has developed new rolled products with an antibacterial coating. It protects the metal surface from dangerous microorganisms and can be successfully used in the decoration of medical facilities and other facilities that have high requirements for cleanliness and safety. The basis of the rolled coating is compounds of copper and silver ions, which destroy the cell membrane of bacteria and fungi upon contact. This makes it possible to reduce the presence of bacteria on the surface of rolled products by 100%. The ions are injected directly into the paint material. This makes the product more resistant to mechanical stress and allows you to maintain the antibacterial effect for decades.The antimicrobial properties of NLMK's rolled products have been confirmed at all stages of development and industrial testing of the technology. They comply with GOST standards and have successfully passed the examination of the Federal Medical and Biological Agency of the Ministry of Health of the Russian Federation.The launch of the product on the market is scheduled for early 2022.
Russian steel maker NLMK Group has developed new rolled products with an antibacterial coating. It protects the metal surface from dangerous microorganisms and can be successfully used in the decoration of medical facilities and other facilities that have high requirements for cleanliness and safety. The basis of the rolled coating is compounds of copper and silver ions, which destroy the cell membrane of bacteria and fungi upon contact. This makes it possible to reduce the presence of bacteria on the surface of rolled products by 100%. The ions are injected directly into the paint material. This makes the product more resistant to mechanical stress and allows you to maintain the antibacterial effect for decades.The antimicrobial properties of NLMK's rolled products have been confirmed at all stages of development and industrial testing of the technology. They comply with GOST standards and have successfully passed the examination of the Federal Medical and Biological Agency of the Ministry of Health of the Russian Federation.The launch of the product on the market is scheduled for early 2022.
